We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
+5.11%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.64B
AUM Growth
+$64M
(+2.5%)
Cap. Flow
-$23.9M
Cap. Flow
% of AUM
-0.91%
Top 10 Holdings %
Top 10 Hldgs %
39.72%
Holding
198
New
11
Increased
45
Reduced
37
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$17.5M |
| 2 |
Stryker
SYK
|
+$12.2M |
| 3 |
AstraZeneca
AZN
|
+$12.1M |
| 4 |
Danaher
DHR
|
+$11.9M |
| 5 |
Pfizer
PFE
|
+$11.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sarepta Therapeutics
SRPT
|
+$13.6M |
| 2 |
SHPG
Shire pic
SHPG
|
+$12.8M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$12.3M |
| 4 |
Abbott
ABT
|
+$10.4M |
| 5 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$8.69M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.61% |
| 2 | Real Estate | 3% |
| 3 | Financials | 0.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
HCA Healthcare
HCA
$85.7B
| $7.7M | 0.29% |
75,090
-16,791
| -18% | -$1.7M |
|
|
ESPR
77
DELISTED
Esperion Therapeutics
ESPR
| $7.42M | 0.28% |
189,287
| – | – |
|
78
Sanofi
SNY
$103B
| $7.2M | 0.27% |
179,900
| – | – |
|
79
Alkermes
ALKS
$8.39B
| $7.04M | 0.27% |
171,042
-39,140
| -19% | -$1.78M |
|
|
WMGI
80
DELISTED
Wright Medical Group Inc
WMGI
| $6.93M | 0.26% |
266,781
| – | – |
|
81
Cigna
CI
$76.1B
| $6.88M | 0.26% |
40,461
-16,102
| -28% | -$2.79M |
|
|
EPZM
82
DELISTED
Epizyme, Inc
EPZM
| $6.58M | 0.25% |
485,325
| – | – |
|
|
NVO
83
Novo Nordisk
NVO
$228B
| $6.27M | 0.24% |
271,800
| – | – |
|
|
DOC
84
DELISTED
PHYSICIANS REALTY TRUST
DOC
| $6.23M | 0.24% |
391,016
+125,680
| +47% | +$1.9M |
|
|
SHPG
85
DELISTED
Shire pic
SHPG
| $6.11M | 0.23% |
36,216
-79,413
| -69% | -$12.8M |
|
86
ResMed
RMD
$30.3B
| $6.07M | 0.23% |
58,630
+24,811
| +73% | +$2.51M |
|
87
Ultragenyx Pharmaceutical
RARE
$2.56B
| $5.92M | 0.22% |
76,958
-71,600
| -48% | -$4.62M |
|
88
Ventas
VTR
$44.7B
| $5.61M | 0.21% |
98,496
+10,500
| +12% | +$550K |
|
89
Tenet Healthcare
THC
$21.8B
| $5.52M | 0.21% |
164,500
| – | – |
|
|
AVDL
90
DELISTED
Avadel Pharmaceuticals
AVDL
| $4.99M | 0.19% |
814,588
| – | – |
|
91
Editas Medicine
EDIT
$413M
| $4.94M | 0.19% |
137,801
| – | – |
|
92
Puma Biotechnology
PBYI
$402M
| $4.93M | 0.19% |
83,340
+27,355
| +49% | +$1.59M |
|
|
MASI
93
DELISTED
Masimo
MASI
| $4.69M | 0.18% |
48,020
+6,354
| +15% | +$604K |
|
94
United Therapeutics
UTHR
$26.2B
| $4.67M | 0.18% |
41,261
| – | – |
|
|
FOMX
95
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $4.66M | 0.18% |
930,398
| – | – |
|
96
Intellia Therapeutics
NTLA
$1.55B
| $4.58M | 0.17% |
167,381
| – | – |
|
97
Bausch Health
BHC
$2.25B
| $4.46M | 0.17% |
192,000
| – | – |
|
|
ALBO
98
DELISTED
Albireo Pharma Inc
ALBO
| $4.44M | 0.17% |
125,000
| – | – |
|
|
ARRY
99
DELISTED
Array Biopharma Inc
ARRY
| $4.3M | 0.16% |
256,056
+100,000
| +64% | +$1.59M |
|
|
NVRO
100
DELISTED
NEVRO CORP.
NVRO
| $4.23M | 0.16% |
52,990
| – | – |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q2 2018 Portfolio in Review
As of Q2 2018, Tekla Capital Management held 198 positions worth $2.64B, up 2.5% from $2.57B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Tekla Capital Management's Q2 2018 filing shows 11 new, 45 increased, 37 reduced and 18 closed positions. Its largest new stake was Whitehawk Therapeutics: 51,000 shares worth $3.17M. The largest sale was Sarepta Therapeutics, an estimated $13.6M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Real Estate and Financials.
- Tekla Capital Management's largest Q2 2018 buy was Whitehawk Therapeutics: 51,000 shares worth $3.17M.
- Tekla Capital Management added most to UnitedHealth in Q2 2018, an estimated $17.5M increase.
- Tekla Capital Management's biggest Q2 2018 reduction was Sarepta Therapeutics, cutting an estimated $13.6M.
- Tekla Capital Management fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $8.69M.
- Tekla Capital Management's ten largest holdings make up 40% of its $2.64B portfolio in Q2 2018.
- Tekla Capital Management opened 11 new positions and closed 18 in Q2 2018.
- Tekla Capital Management's portfolio value rose 2.5% quarter-over-quarter to $2.64B.
Based on Tekla Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.